Daiichi Sankyo and AstraZeneca’s (AZN) Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor positive, HER2 low or HER2 ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next line of treatment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca data ‘positive’ for Olema’s palazestrant, says H.C. Wainwright
- AstraZeneca reports SERENA-6 trial shows improvement in the primary endpoint
- AstraZeneca announces results from interim analysis of SERENA-6 Phase III trial
- AstraZeneca’s Promising Pipeline and Positive Trial Results Justify Buy Rating
- AIM ImmunoTech doses first subject in Phase 2 study of Ampligen, Imfinzi